MedImmune (development and commercial rights of HMGB1) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Grant

  • Financing Rounds
  • 2

MedImmune (development and commercial rights of HMGB1) General Information

Description

The portfolio is a right to develop high-mobility group box protein 1 (HMGB1). The HMGB1 is a DNA-binding protein which regulates gene transcription and stabilizes nucleosome formation. It also endogenous mediator of tissue injury, initiated by pro-inflammatory cytokines.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • MD
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Drug Discovery
Acquirer
Chiesi USA
Vertical(s)
Life Sciences
Corporate Office
  • MD
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MedImmune (development and commercial rights of HMGB1) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MedImmune (development and commercial rights of HMGB1)‘s full profile, request access.

Request a free trial

MedImmune (development and commercial rights of HMGB1) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MedImmune (development and commercial rights of HMGB1)‘s full profile, request access.

Request a free trial

MedImmune (development and commercial rights of HMGB1) FAQs

  • Where is MedImmune (development and commercial rights of HMGB1) headquartered?

    MedImmune (development and commercial rights of HMGB1) is headquartered in MD.

  • What industry is MedImmune (development and commercial rights of HMGB1) in?

    MedImmune (development and commercial rights of HMGB1)’s primary industry is Buildings and Property.

  • Is MedImmune (development and commercial rights of HMGB1) a private or public company?

    MedImmune (development and commercial rights of HMGB1) is a Private company.

  • What is MedImmune (development and commercial rights of HMGB1)’s current revenue?

    The current revenue for MedImmune (development and commercial rights of HMGB1) is .

  • Who are MedImmune (development and commercial rights of HMGB1)’s investors?

    MedImmune has invested in MedImmune (development and commercial rights of HMGB1).

  • When was MedImmune (development and commercial rights of HMGB1) acquired?

    MedImmune (development and commercial rights of HMGB1) was acquired on 01-Jun-2015.

  • Who acquired MedImmune (development and commercial rights of HMGB1)?

    MedImmune (development and commercial rights of HMGB1) was acquired by Chiesi USA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process